

NCT NO	Drug	Other treatment	Trial Design	Trial Phase	Start	End	Last Update posted	No of Enrolled Patients	Incidence of Recurrence and Metastasis After Hepatectomy	OS(months) Overall Survival	RFS(months) Recurrence-Free Survival	PFS (months) Progression-Free Survival	ORR(%) Objective Response Rate	TTR(months) Time to Recurrence	TTS(months) Time to Systemic Progression	TTP (months) Time to Tumor Progression	DR (months) duration of response	DCR(%)	CBR Percentage of Participants With Overall Clinical Benefit	Reference PMID	Target Pathways
NCT01210495	Axitinib (AG-137376) VS. Placebo	Best Supportive care (BSC)	Randomized Parallel assignment Double-Blind	2	Dec 2010	Dec 2016	03-28-2017	224		12.7(10.2-14.9) 8.7(5.9-11.1) p=0.2872		1.6(2.3-4.6) 1.9(1.5-5.5) p=0.0039	9.7(5.3-16) 2.9(0.4-10.2) p=0.0914			7.2(3.5-6) 1.9(1.8-3.6) p=0.006	6.4(3.7-9.3) NA	11.3(21.6-39.9) 11.8(2.2-1.9) p=0.0025	26386123	VEGFR, PDGFR	
NCT01140347	Ramucirumab (DP-131211B) VS. Placebo	BSC	Randomized Parallel assignment Double-Blind	3	October 2010	March 2015	28-Dec-15	565		9.17 (8.05 to 10.64) 7.62(6.01-9.33) p=0.1591		2.79 (2.69 to 3.94) 2.10 (1.58 to 2.69) p=0.0001	1.1 (4.6 to 10.7) 9.7 (0.2 to 2.5) p=0.0001			3.48 (2.76 to 4.47) 2.63 (1.58 to 2.76) p=0.0001		27657524 26095784	VEGFR2		
NCT01232296	Doxorubicin VS. Sorafenib		Randomized Parallel assignment Open Label	2	July 2011	April 2014	04-Dec-15	165		13.125.7 to 39) 29.4(22.6 to 56.1)						17.6 (12.3 to 18.4) 17.9 (12.3 to 18.9)				VEGFR, VEGFR, PDGFR3, F3, c-KIT (Doxorubicin)	
NCT01203787	Sorafenib Standard Dosing Regimen VS. Sorafenib Ramp-Up Regimen		Randomized Parallel assignment Open Label	4	Dec 2010	March 2014	05-Mar-15	120													Ref. VEGFR2/PDGFR
NCT00698616	Immunocell-LC VS. Control		Randomized Parallel assignment Open Label	3	Jul 2008	Nov 2012	9-24-2015	250		N/A N/A p=0.008	44(2.46-44.54) NA p=0.01									25742273	
NCT01379521	Everolimus VS. Placebo	FAZE	Randomized Parallel assignment Quadruple-Blind	2	Jun 2011	June 2015	5-3-2017	65		29.9 (12.0 to N/A) 21.7 (19.4 to 27.9)						6.3(4.3-6.6) 6.4(4.4-9)				mTOR	
NCT00699374	Sunitinib Malate VS. Sorafenib		Randomized Parallel assignment Open Label	3	Jul 2008	Dec 2011	1-14-2013	1075		34.3 (31.9 to 39.9) 43.9 (38.1 to 48.7) p=0.0093		15.3 (12.1 to 17.7) 12.6 (12.1 to 17.3) p=0.8857				17.7 (13.6 to 18.0) 15.4 (12.3 to 18.1) p=0.8459		24081937 20201173	VEGFR2, PDGFR, c-KIT, FRS		
NCT00817151	Bevacizumab + Erlotinib VS. Sorafenib		Randomized Parallel assignment Open Label	2	Mar 2009	Feb 2017	11-Sep-17	95		8.55 (7.00 to 13.9) 8.55 (5.69 to 12.2)		4.37 (2.99 to 7.36) 2.76 (1.84 to 4.89)									VEGFR(Bevacizumab) EGFR(Erlotinib)
NCT00494322	Bevacizumab VS. Control	FAZE	Randomized Crossover assignment Open Label	2	June 2003	Feb 2012	15-Mar-16	30													VEGF
NCT01770413	Isatin Granule VS. Blank Control		Randomized Parallel assignment Double-Blind	4	Aug 2011	Aug 2016	Oct-2-2017	1044	37.6% 50.9% p=0.0001	75.5(1.15 SE) 68.5(1.89 SE) p=0.0001											modulation of various pathways in carcinogenesis and angiogenesis
NCT01089953	Sorafenib + Docarubicin VS. Placebo+Docarubicin		Randomized Parallel assignment Double-Blind		Apr 2005	Apr 2008	31-Oct-14	96		13.9(10.57-N/A) 6.6(4.95-10.06) p=0.007		8.07(4.67-10.4) 2.8(2.37-5.73) p=0.014			8.73(4.87-12.8) 4.9(2.8-11) p=0.016					Ref. VEGFR2/PDGFR	
NCT00692770	Sorafenib VS. placebo		Randomized Parallel assignment Quadruple-Blind	3	Aug 15, 2008	Nov 28, 2011	16-Oct-17	1114		NA NA p=0.484742	33.8(27.91-44.63) 34.2(28.03-39.5) p=0.258329			18.5(13.0-NA) NA p=0.12382			2.96 (2.79 to 4.01) 2.60 (1.48 to 2.83)	56.1 45.1	25058216	mTOR	
NCT01015229	Everolimus VS. Placebo	BSC	Randomized Parallel assignment Double-Blind	3	April 2010	Oct 2013	22-Sep-16	546		7.56 (6.70 to 8.74) 7.33 (6.28 to 8.74)						2.96 (2.79 to 4.01) 2.60 (1.48 to 2.83)				mTOR	
NCT01054443	Sorafenib VS. Placebo		Randomized Parallel assignment Double-Blind	3	March 2005	Nov 2008	31-Oct-14	602		10.8(9.53 to 13.5) 8.03 (6.37 to 9.2) p=0.00045					4.2(3.3-4.2) 4.9(4.3-6.4) p=0.00007	5.6(4.2-7) 3.7(2.73-4) p=0.00007		18650514	VEGFR2/PDGFR		
NCT00492372	Sorafenib VS. Placebo		Randomized Parallel assignment Triple-Blind	3	Oct 2005	Jul 2009	16-Ags-14	226		8.4 (5.63 to 7.67) 4.23 (3.8 to 5.53) p=0.14144					3.5 (2.83 to 4.3) 3.43 (2.43 to 4.13) p=0.000537	2.8 (2.67 to 3.63) 1.38 (1.37 to 1.57) p=0.000537		19085497 22240382	Ref. VEGFR2/PDGFR		
NCT00987935	BBF 1120 VS. Sorafenib		Randomized Parallel assignment Open Label	2	Oct 2009	Jan 2016	10-Mar-16	134		10.185 (9.19 to 16.85) 10.71 (7.29 to 16.66)		2.66 (0.99 to 5.55) 1.71 (1.77 to 7.36)				2.76 (0.99 to 5.55) 3.71(1.77 to 7.36)					
NCT00855218	Sorafenib VS. Placebo	FAZE	Randomized Parallel assignment Quadruple-Blind	2	March 2009	Feb 2013	18-Aug-17	307		NA(18.47-N/A) NA(18.73-N/A) p=0.295						5.63(5.53-7.3) 5.53(3.73-5.6) p=0.072		26809111	Ref. VEGFR2/PDGFR		

Table 1. Complete randomized clinical trials targeting inflammation in HCC

Interventional clinical trials in HCC that match the following criteria in ClinicalTrials.gov were selected: (1) terminated or completed studies, (2) with results, (3) phase 2 or 3 or 4, (4) drugs targeting inflammation-associated pathways, (5) allocation: randomized, and (6) intervention model: parallel or crossover design.